跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 438 条关于
“ODAC”
全部
438
临床试验
306
药物
67
机构
5
资讯
60
2年前
FDA Panel Endorses Minimal Residual Disease (MRD) as Endpoint for Accelerated Approval in Multiple Myeloma
去年
FDA's ODAC to Review Four Cancer Drugs in May Meeting
去年
ODAC Weighs PD-L1 Expression as Predictive Biomarker for Immunotherapy in Esophageal Cancer
2年前
ODAC Recommends Enhanced Trial Designs for Perioperative NSCLC Regimens Following Durvalumab Approval
去年
FDA Advisory Committee Votes 6-2 in Favor of Daratumumab for High-Risk Smoldering Multiple Myeloma
去年
FDA Reviews Accelerated Approvals for Keytruda, Opdivo, and Tecentriq in Multiple Cancers
2年前
FDA Panel Supports Eflornithine for High-Risk Pediatric Neuroblastoma
去年
FDA Advisory Committee Recommends Against Checkpoint Inhibitors for Certain Gastroesophageal Cancers
去年
FDA Advisory Committee Rejects Genentech's Columvi Expansion for Transplant-Ineligible DLBCL Patients
去年
FDA's Approval of MRD as End Point Transforms Multiple Myeloma Research and Treatment
第 1 页,共 6 页
上一页
下一页